Table 1.
Patient characteristics.
| Characteristic | 3DCRT (n = 56) | IMRT (n = 30) | P value |
|---|---|---|---|
| Mean age (years) | 56.3 | 52.7 | 0.23 |
| Male/female (n) (%) | 40/16 (71/29) | 15/15 (50/50) | 0.06 |
| Total elapsed days (mean) | 40.5 | 38.7 | 0.081 |
| Treatment suspended (n) (%) | 11 (20%) | 0 (0) | 0.0002 |
| Median total dose (cGy) | 5040 | 5040 | 0.23 |
|
| |||
| Chemotherapy types (n) (%) | 0.71 | ||
| Capecitabine or 5-FU | 45 (80) | 27 (90) | |
| Capecitabine/oxaliplatin | 7(12) | 3 (10) | |
| Capecitabine/CPT-11 | 1 (2) | 0 | |
| 5-FU/leucovorin/oxaliplatin | 3 (5) | 0 | |
|
| |||
| Preoperative T stage (n) (%) | 0.85 | ||
| T2 | 0 | 1 (3) | |
| T3 | 51 (91) | 27 (90) | |
| T4 | 5 (9) | 2 (7) | |
|
| |||
| Preoperative N stage (n) (%) | 0.21 | ||
| N0/x | 26 (46) | 10 (33) | |
| N1/N2 | 30 (54) | 20 (67) | |
|
| |||
| Preoperative M stage (n)% | 0.91 | ||
| M0 | 52 (93) | 27 (90) | |
| M1 | 4 (7) | 3 (10) | |
|
| |||
| Pathological complete response (%) | 21% | 20% | 0.555 |
| Downstaging T stage (%) | 50 | 60 | 0.26 |
| Downstaging N stage (%) | 34 | 40 | 0.37 |